Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Jun 19, 2013 ·
6m 9s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second...
show more
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
show less
Information
Author | cancerGRACE |
Organization | cancerGRACE |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company